Singapore markets close in 7 hours 59 minutes
  • Straits Times Index

    +5.98 (+0.18%)
  • Nikkei

    +132.53 (+0.47%)
  • Hang Seng

    -165.29 (-0.68%)
  • FTSE 100

    +68.28 (+0.91%)

    -584.57 (-1.36%)
  • CMC Crypto 200

    -5.63 (-0.55%)
  • S&P 500

    +3.82 (+0.08%)
  • Dow

    -201.79 (-0.56%)
  • Nasdaq

    +86.95 (+0.59%)
  • Gold

    +3.10 (+0.17%)
  • Crude Oil

    +0.34 (+0.41%)
  • 10-Yr Bond

    +0.0610 (+3.57%)
  • FTSE Bursa Malaysia

    -12.41 (-0.80%)
  • Jakarta Composite Index

    -48.35 (-0.72%)
  • PSE Index

    -37.51 (-0.52%)

Nova Mentis to Present at the H.C. Wainwright Psychedelics Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

VANCOUVER, BC, Dec. 2, 2021 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it will present at the H.C. Wainwright Psychedelics Conference on December 6, 2021.

"The psychedelic industry is still in its infancy and what is required to bring needed medical therapy in this restricted, regulated market is to develop drugs in a classic pharmaceutical approach. This approach is based upon strict quality controls of the produced therapeutic agent, behavioural results confirmed with known biologic markers, and minimal side effects," says Dr. Marvin S. Hausman, Chairman of NOVA's Scientific Advisory Board.

In his presentation, Dr. Hausman will reveal significant new findings and technology to show the physiologic application of microdose psychedelic therapy and positive genetic confirmatory response.

His presentation will be available on-demand starting at 7:00 a.m. EST on December 6, 2021. Click here to register for the conference and schedule a one-on-one meeting with Dr. Hausman.

NOVA is leading a psilocybin-based therapeutics and diagnostics program for neuroinflammatory disorders and is the first biotech company to receive psilocybin orphan drug designation in both the U.S. and European Union, which will greatly assist the company on the pathway to drug approval.

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders.

The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and Fragile X Syndrome (FXS).

On Behalf of the Board

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

SOURCE Nova Mentis Life Science Corp.


View original content:

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting